全文获取类型
收费全文 | 334468篇 |
免费 | 19928篇 |
国内免费 | 455篇 |
专业分类
耳鼻咽喉 | 4837篇 |
儿科学 | 12013篇 |
妇产科学 | 11231篇 |
基础医学 | 49487篇 |
口腔科学 | 9387篇 |
临床医学 | 27602篇 |
内科学 | 63753篇 |
皮肤病学 | 7354篇 |
神经病学 | 24206篇 |
特种医学 | 12822篇 |
外国民族医学 | 43篇 |
外科学 | 52887篇 |
综合类 | 7891篇 |
现状与发展 | 1篇 |
一般理论 | 177篇 |
预防医学 | 22353篇 |
眼科学 | 7906篇 |
药学 | 23350篇 |
中国医学 | 944篇 |
肿瘤学 | 16607篇 |
出版年
2021年 | 2892篇 |
2019年 | 2983篇 |
2018年 | 4923篇 |
2017年 | 3590篇 |
2016年 | 4084篇 |
2015年 | 4356篇 |
2014年 | 5591篇 |
2013年 | 8915篇 |
2012年 | 11863篇 |
2011年 | 12795篇 |
2010年 | 7602篇 |
2009年 | 6393篇 |
2008年 | 11484篇 |
2007年 | 12540篇 |
2006年 | 12295篇 |
2005年 | 11865篇 |
2004年 | 11447篇 |
2003年 | 10766篇 |
2002年 | 10199篇 |
2001年 | 14042篇 |
2000年 | 14463篇 |
1999年 | 11886篇 |
1998年 | 3235篇 |
1997年 | 2965篇 |
1996年 | 2788篇 |
1995年 | 2675篇 |
1994年 | 2457篇 |
1992年 | 8403篇 |
1991年 | 8516篇 |
1990年 | 8334篇 |
1989年 | 8140篇 |
1988年 | 7359篇 |
1987年 | 7108篇 |
1986年 | 6752篇 |
1985年 | 6548篇 |
1984年 | 4801篇 |
1983年 | 4152篇 |
1982年 | 2516篇 |
1979年 | 4454篇 |
1978年 | 3249篇 |
1977年 | 2763篇 |
1976年 | 2519篇 |
1975年 | 2841篇 |
1974年 | 3363篇 |
1973年 | 3376篇 |
1972年 | 3123篇 |
1971年 | 2951篇 |
1970年 | 2840篇 |
1969年 | 2584篇 |
1968年 | 2540篇 |
排序方式: 共有10000条查询结果,搜索用时 22 毫秒
21.
22.
23.
Claire Letournel François Babinet Bénédicte Allard Vincent Montecot 《Néphrologie & thérapeutique》2019,15(1):51-58
Objective
The “Centre Hospitalier Francois Dunan” is located on an isolated island and ensures patients care in hemodialysis thanks to telemedicine support. Many research studies have demonstrated the importance of hemodialysis fluids composition to reduce morbidity in patients on chronic hemodialysis. The aim of this study was to identify the risks inherent in the production of dialysis fluids in a particular context, in order to set up an improvement action plan to improve risk control on the production of dialysis fluids.Methods
The risk analysis was conducted with the FMECA methodology (Failure Mode, Effects and Criticality Analysis) by a multi professional work group. Three types of risk have been reviewed: technical risks that may impact the production of hemodialysis fluids, health risks linked with chemical composition and health risks due to microbiological contamination of hemodialysis fluids.Results
The work group, in close cooperation with the expert staff of the dialysis center providing telemedicine assistance, has developed an action plan in order to improve the control of the main risks brought to light by the risk analysis.Conclusion
The exhaustive analysis of the risks and their prioritisation have permitted to establish a relevant action plan in this improving quality of dialysis fluids approach. The risk control of dialysis fluids is necessary for the security of dialysis sessions for patients, even more when these sessions are realized by telemedicine in Saint-Pierre-et-Miquelon. 相似文献24.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
25.
26.
27.
28.
29.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers
下载免费PDF全文
![点击此处可从《Clinical endocrinology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
30.